Your browser doesn't support javascript.
loading
Differences in polygenic score distributions in European ancestry populations: implications for breast cancer risk prediction.
Yiangou, Kristia; Mavaddat, Nasim; Dennis, Joe; Zanti, Maria; Wang, Qin; Bolla, Manjeet K; Abubakar, Mustapha; Ahearn, Thomas U; Andrulis, Irene L; Anton-Culver, Hoda; Antonenkova, Natalia N; Arndt, Volker; Aronson, Kristan J; Augustinsson, Annelie; Baten, Adinda; Behrens, Sabine; Bermisheva, Marina; de Gonzalez, Amy Berrington; Bialkowska, Katarzyna; Boddicker, Nicholas; Bodelon, Clara; Bogdanova, Natalia V; Bojesen, Stig E; Brantley, Kristen D; Brauch, Hiltrud; Brenner, Hermann; Camp, Nicola J; Canzian, Federico; Castelao, Jose E; Cessna, Melissa H; Chang-Claude, Jenny; Chenevix-Trench, Georgia; Chung, Wendy K; Colonna, Sarah V; Couch, Fergus J; Cox, Angela; Cross, Simon S; Czene, Kamila; Daly, Mary B; Devilee, Peter; Dörk, Thilo; Dunning, Alison M; Eccles, Diana M; Eliassen, A Heather; Engel, Christoph; Eriksson, Mikael; Evans, D Gareth; Fasching, Peter A; Fletcher, Olivia; Flyger, Henrik.
Afiliação
  • Yiangou K; Biostatistics Unit, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus, 2371.
  • Mavaddat N; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK, CB1 8RN.
  • Dennis J; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK, CB1 8RN.
  • Zanti M; Biostatistics Unit, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus, 2371.
  • Wang Q; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK, CB1 8RN.
  • Bolla MK; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK, CB1 8RN.
  • Abubakar M; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA, 20850.
  • Ahearn TU; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA, 20850.
  • Andrulis IL; Fred A, Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada, M5G 1X5.
  • Anton-Culver H; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada, M5S 1A8.
  • Antonenkova NN; Department of Medicine, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, CA, USA, 92617.
  • Arndt V; NN Alexandrov Research Institute of Oncology and Medical Radiology, Minsk, Belarus, 223040.
  • Aronson KJ; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany, 69120.
  • Augustinsson A; Department of Public Health Sciences, and Cancer Research Institute, Queen's University, Kingston, ON, Canada, K7L 3N6.
  • Baten A; Oncology, Clinical Sciences in Lund, Lund University, Lund, Sweden, 221 85.
  • Behrens S; Leuven Multidisciplinary Breast Center, Department of Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium, 3000.
  • Bermisheva M; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany, 69120.
  • de Gonzalez AB; Institute of Biochemistry and Genetics of the Ufa Federal Research Centre of the Russian Academy of Sciences, Ufa, Russia, 450054.
  • Bialkowska K; St Petersburg State University, St, Petersburg, Russia, 199034.
  • Boddicker N; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK, SM2 5NG.
  • Bodelon C; Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland, 71-252.
  • Bogdanova NV; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA, 55905.
  • Bojesen SE; Department of Population Science, American Cancer Society, Atlanta, GA, USA, 30303.
  • Brantley KD; NN Alexandrov Research Institute of Oncology and Medical Radiology, Minsk, Belarus, 223040.
  • Brauch H; Department of Radiation Oncology, Hannover Medical School, Hannover, Germany, 30625.
  • Brenner H; Gynaecology Research Unit, Hannover Medical School, Hannover, Germany, 30625.
  • Camp NJ; Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark, 2730.
  • Canzian F; Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark, 2730.
  • Castelao JE; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, 2200.
  • Cessna MH; Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA, 02115.
  • Chang-Claude J; Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany, 70376.
  • Chenevix-Trench G; iFIT-Cluster of Excellence, University of Tübingen, Tübingen, Germany, 72074.
  • Chung WK; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Tübingen, Tübingen, Germany, 72074.
  • Colonna SV; Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany, 69120.
  • Couch FJ; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany, 69120.
  • Cox A; Department of Internal Medicine and Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA, 84112.
  • Cross SS; Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany, 69120.
  • Czene K; Oncology and Genetics Unit, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS) Foundation, Complejo Hospitalario Universitario de Santiago, SERGAS, Vigo, Spain, 36312.
  • Daly MB; Department of Pathology, Intermountain Healthcare, Salt Lake City, UT, USA, 84143.
  • Devilee P; Intermountain Biorepository, Intermountain Healthcare, Salt Lake City, UT, USA, 84143.
  • Dörk T; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany, 69120.
  • Dunning AM; Cancer Epidemiology Group, University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 20246.
  • Eccles DM; Cancer Research Program, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia, 4006.
  • Eliassen AH; Departments of Pediatrics and Medicine, Columbia University, New York, NY, USA, 10032.
  • Eriksson M; Department of Internal Medicine and Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA, 84112.
  • Evans DG; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA, 55905.
  • Fasching PA; Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK, S10 2TN.
  • Fletcher O; Division of Neuroscience, School of Medicine and Population Health, University of Sheffield, Sheffield, UK, S10 2TN.
  • Flyger H; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden, 171 65.
medRxiv ; 2024 Feb 13.
Article em En | MEDLINE | ID: mdl-38410445
ABSTRACT
The 313-variant polygenic risk score (PRS313) provides a promising tool for breast cancer risk prediction. However, evaluation of the PRS313 across different European populations which could influence risk estimation has not been performed. Here, we explored the distribution of PRS313 across European populations using genotype data from 94,072 females without breast cancer, of European-ancestry from 21 countries participating in the Breast Cancer Association Consortium (BCAC) and 225,105 female participants from the UK Biobank. The mean PRS313 differed markedly across European countries, being highest in south-eastern Europe and lowest in north-western Europe. Using the overall European PRS313 distribution to categorise individuals leads to overestimation and underestimation of risk in some individuals from south-eastern and north-western countries, respectively. Adjustment for principal components explained most of the observed heterogeneity in mean PRS. Country-specific PRS distributions may be used to calibrate risk categories in individuals from different countries.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article